|
ATE442152T1
(de)
|
2002-11-18 |
2009-09-15 |
Santaris Pharma As |
Antisense-entwurf
|
|
DK2379084T3
(en)
|
2008-10-15 |
2018-01-22 |
Ionis Pharmaceuticals Inc |
MODULATION OF FACTOR 11 EXPRESSION
|
|
AU2009323766B2
(en)
|
2008-12-02 |
2016-10-06 |
Wave Life Sciences Ltd. |
Method for the synthesis of phosphorus atom modified nucleic acids
|
|
SG177564A1
(en)
|
2009-07-06 |
2012-02-28 |
Ontorii Inc |
Novel nucleic acid prodrugs and methods of use thereof
|
|
EP2620428B1
(en)
|
2010-09-24 |
2019-05-22 |
Wave Life Sciences Ltd. |
Asymmetric auxiliary group
|
|
WO2012068405A2
(en)
|
2010-11-17 |
2012-05-24 |
Isis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
|
US9605019B2
(en)
|
2011-07-19 |
2017-03-28 |
Wave Life Sciences Ltd. |
Methods for the synthesis of functionalized nucleic acids
|
|
US9580708B2
(en)
|
2011-09-14 |
2017-02-28 |
Rana Therapeutics, Inc. |
Multimeric oligonucleotides compounds
|
|
KR20150030205A
(ko)
|
2012-05-16 |
2015-03-19 |
라나 테라퓨틱스, 인크. |
Smn 유전자 패밀리 발현을 조절하기 위한 조성물 및 방법
|
|
EP2850185A4
(en)
|
2012-05-16 |
2015-12-30 |
Rana Therapeutics Inc |
COMPOSITIONS AND METHOD FOR MODULATING UTRN GENE EXPRESSION
|
|
CN104583401A
(zh)
|
2012-05-16 |
2015-04-29 |
Rana医疗有限公司 |
用于调节atp2a2表达的组合物和方法
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
CA2873779A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating mecp2 expression
|
|
BR112014028631A2
(pt)
|
2012-05-16 |
2017-10-17 |
Rana Therapeutics Inc |
composições e métodos para modulação da expressão da família de genes da hemoglobina
|
|
SG10201912895PA
(en)
|
2012-07-13 |
2020-02-27 |
Wave Life Sciences Ltd |
Chiral control
|
|
JP6268157B2
(ja)
|
2012-07-13 |
2018-01-24 |
株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ |
不斉補助基
|
|
EP2895200B1
(en)
|
2012-09-14 |
2019-11-06 |
Translate Bio MA, Inc. |
Multimeric oligonucleotide compounds
|
|
ES2724853T3
(es)
|
2012-11-15 |
2019-09-16 |
Roche Innovation Ct Copenhagen As |
Conjugados de oligonucleótidos
|
|
MY177989A
(en)
*
|
2013-01-30 |
2020-09-28 |
Hoffmann La Roche |
Lna oligonucleotide carbohydrate conjugates
|
|
EA034731B1
(ru)
|
2013-05-01 |
2020-03-13 |
Регьюлэс Терапьютикс Инк. |
Соединения на основе микрорнк и способы модулирования активности mir-122
|
|
WO2014179445A1
(en)
|
2013-05-01 |
2014-11-06 |
Regulus Therapeutics Inc. |
Compounds and methods for enhanced cellular uptake
|
|
KR102138781B1
(ko)
|
2013-05-01 |
2020-07-28 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포지질단백질 c-iii 발현을 조절하는 조성물 및 방법
|
|
WO2015042447A1
(en)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
EP3060664B1
(en)
|
2013-10-25 |
2021-07-07 |
Sanofi |
Microrna compounds and methods for modulating mir-21 activity
|
|
JPWO2015108048A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
JPWO2015108047A1
(ja)
|
2014-01-15 |
2017-03-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
|
PT3094728T
(pt)
|
2014-01-16 |
2022-05-19 |
Wave Life Sciences Ltd |
Desenho quiral
|
|
EP3099797B1
(en)
|
2014-01-30 |
2019-08-21 |
F. Hoffmann-La Roche AG |
Poly oligomer compound with biocleavable conjugates
|
|
HRP20211397T1
(hr)
|
2014-03-19 |
2021-12-10 |
Ionis Pharmaceuticals, Inc. |
Pripravci za modulaciju ekspresije ataksina 2
|
|
US10006027B2
(en)
|
2014-03-19 |
2018-06-26 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating Ataxin 2 expression
|
|
LT3126499T
(lt)
|
2014-04-01 |
2020-07-27 |
Biogen Ma Inc. |
Kompozicijos, skirtos sod-1 ekspresijos moduliavimui
|
|
US9382540B2
(en)
|
2014-05-01 |
2016-07-05 |
Isis Pharmaceuticals, Inc |
Compositions and methods for modulating angiopoietin-like 3 expression
|
|
DK3137091T3
(da)
|
2014-05-01 |
2021-01-25 |
Ionis Pharmaceuticals Inc |
Konjugater af modificerede antisense-oligonukleotider og anvendelse deraf til modulation af pkk-ekspression
|
|
US9994855B2
(en)
|
2014-05-01 |
2018-06-12 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating growth hormone receptor expression
|
|
PT3137596T
(pt)
|
2014-05-01 |
2019-09-27 |
Ionis Pharmaceuticals Inc |
Composições e métodos para modulação da expressão do factor b do complemento
|
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
|
BR112017001931A2
(pt)
*
|
2014-08-07 |
2017-11-28 |
Regulus Therapeutics Inc |
direcionamento de micrornas para distúrbios metabólicos
|
|
WO2016040748A1
(en)
|
2014-09-12 |
2016-03-17 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for detection of smn protein in a subject and treatment of a subject
|
|
RU2017114156A
(ru)
|
2014-10-10 |
2018-11-15 |
Ф. Хоффманн-Ля Рош Аг |
N-ацетилгалактозаминовые (galnac) фосфорамитиды, их конъюгаты с нуклеиновыми кислотами и их применение
|
|
EP3218486A1
(en)
*
|
2014-11-10 |
2017-09-20 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Combination long acting compositions and methods for hepatitis c
|
|
WO2016096938A1
(en)
|
2014-12-16 |
2016-06-23 |
Roche Innovation Center Copenhagen A/S |
Chiral toxicity screening method
|
|
JP2018504380A
(ja)
|
2014-12-18 |
2018-02-15 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｒｅｖｅｒｓｉｒ（商標）化合物
|
|
US10793855B2
(en)
|
2015-01-06 |
2020-10-06 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of C9ORF72 antisense transcript
|
|
WO2016115490A1
(en)
|
2015-01-16 |
2016-07-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of dux4
|
|
WO2016130943A1
(en)
*
|
2015-02-13 |
2016-08-18 |
Rana Therapeutics, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
RS62672B1
(sr)
|
2015-04-03 |
2021-12-31 |
Univ Massachusetts |
Oligonukleotidna jedinjenja za tretman preeklampsije i drugih angiogenskih poremećaja
|
|
US9809817B2
(en)
|
2015-04-03 |
2017-11-07 |
University Of Massachusetts |
Oligonucleotide compounds for targeting huntingtin mRNA
|
|
JP6892433B2
(ja)
|
2015-04-03 |
2021-06-23 |
ユニバーシティ・オブ・マサチューセッツＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍａｓｓａｃｈｕｓｅｔｔｓ |
十分に安定化された非対称ｓｉｒｎａ
|
|
HK1249140A1
(zh)
|
2015-04-03 |
2018-10-26 |
Ionis Pharmaceuticals, Inc. |
用於调节tmprss6表达的化合物和方法
|
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
US10633653B2
(en)
|
2015-08-14 |
2020-04-28 |
University Of Massachusetts |
Bioactive conjugates for oligonucleotide delivery
|
|
JP6835826B2
(ja)
|
2015-08-24 |
2021-02-24 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Ｌｎａ−ｇプロセス
|
|
EP3353305A4
(en)
*
|
2015-09-25 |
2019-09-18 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
EP3355932B1
(en)
|
2015-10-02 |
2023-04-12 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugation process
|
|
CN114533900A
(zh)
|
2015-10-09 |
2022-05-27 |
波涛生命科学有限公司 |
寡核苷酸组合物及其方法
|
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
|
LT4119569T
(lt)
*
|
2015-11-06 |
2024-09-25 |
Ionis Pharmaceuticals, Inc. |
Konjuguoti priešprasmiai junginiai, skirti panaudoti terapijoje
|
|
KR20250078597A
(ko)
|
2015-11-06 |
2025-06-02 |
아이오니스 파마수티컬즈, 인코포레이티드 |
아포리포프로테인 (a) 발현 조정
|
|
CN108350431A
(zh)
|
2015-11-12 |
2018-07-31 |
豪夫迈·罗氏有限公司 |
用于确定候选药物的功效特征的方法
|
|
WO2017096395A1
(en)
|
2015-12-04 |
2017-06-08 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
|
CA3006015A1
(en)
|
2015-12-31 |
2017-07-06 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing ataxin-2 expression
|
|
EP3400300A4
(en)
|
2016-01-05 |
2019-08-07 |
Ionis Pharmaceuticals, Inc. |
PROCESS FOR REDUCING LRRK2 EXPRESSION
|
|
CA3012967A1
(en)
*
|
2016-01-29 |
2017-08-03 |
Kyowa Hakko Kirin Co., Ltd. |
Nucleic acid conjugate
|
|
US10478503B2
(en)
|
2016-01-31 |
2019-11-19 |
University Of Massachusetts |
Branched oligonucleotides
|
|
JOP20170057B1
(ar)
|
2016-03-07 |
2022-03-14 |
Arrowhead Pharmaceuticals Inc |
مركبات ترابطية مستهدفة كمركبات علاجية
|
|
PT3430141T
(pt)
|
2016-03-14 |
2021-02-25 |
Hoffmann La Roche |
Oligonucleótidos para redução da expressão de pd-l1
|
|
US10961271B2
(en)
|
2016-03-16 |
2021-03-30 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
|
MA45328A
(fr)
*
|
2016-04-01 |
2019-02-06 |
Avidity Biosciences Llc |
Compositions acide nucléique-polypeptide et utilisations de celles-ci
|
|
EP3228326A1
(en)
*
|
2016-04-05 |
2017-10-11 |
Silence Therapeutics GmbH |
Nucleic acid linked to a trivalent glycoconjugate
|
|
WO2017177169A1
(en)
*
|
2016-04-08 |
2017-10-12 |
Rana Therapeutics, Inc. |
Multimeric coding nucleic acid and uses thereof
|
|
CN109153697A
(zh)
|
2016-04-14 |
2019-01-04 |
豪夫迈·罗氏有限公司 |
三苯甲基-单-GalNAc化合物及其用途
|
|
CN109475568A
(zh)
*
|
2016-05-06 |
2019-03-15 |
Ionis制药公司 |
Glp-1受体配体部分缀合的寡核苷酸及其用途
|
|
MA45496A
(fr)
|
2016-06-17 |
2019-04-24 |
Hoffmann La Roche |
Molécules d'acide nucléique pour la réduction de l'arnm de padd5 ou pad7 pour le traitement d'une infection par l'hépatite b
|
|
WO2017219017A1
(en)
|
2016-06-17 |
2017-12-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of gys1 expression
|
|
EP3475424A1
(en)
|
2016-06-22 |
2019-05-01 |
ProQR Therapeutics II B.V. |
Single-stranded rna-editing oligonucleotides
|
|
RU2019101298A
(ru)
|
2016-07-01 |
2020-08-03 |
Ф. Хоффманн-Ля Рош Аг |
Антисмысловые олигонуклеотиды для модулирования экспрессии htra1
|
|
WO2018031933A2
(en)
|
2016-08-12 |
2018-02-15 |
University Of Massachusetts |
Conjugated oligonucleotides
|
|
CN110352244B
(zh)
|
2016-09-01 |
2023-03-21 |
ProQR治疗上市公司Ⅱ |
化学修饰的编辑rna的单链寡核苷酸
|
|
IL300869A
(en)
|
2016-09-02 |
2023-04-01 |
Arrowhead Pharmaceuticals Inc |
Ligands containing a targeting factor, preparations containing them and their uses
|
|
US11400161B2
(en)
|
2016-10-06 |
2022-08-02 |
Ionis Pharmaceuticals, Inc. |
Method of conjugating oligomeric compounds
|
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
US11033570B2
(en)
|
2016-12-02 |
2021-06-15 |
Cold Spring Harbor Laboratory |
Modulation of Lnc05 expression
|
|
WO2018130582A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
|
EP3568480A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb2 expression
|
|
US20200216845A1
(en)
|
2017-01-13 |
2020-07-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
|
EP3568479A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb1 expression
|
|
EP3568481A1
(en)
|
2017-01-13 |
2019-11-20 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating relb expression
|
|
EP3594346A4
(en)
|
2017-03-10 |
2020-12-16 |
National Center For Child Health And Development |
ANTISENS OLIGONUCLEOTIDE AND COMPOSITION FOR THE PREVENTION OR TREATMENT OF TYPE IA GLYCOGEN STORAGE DISEASE
|
|
WO2018165541A1
(en)
*
|
2017-03-10 |
2018-09-13 |
The Board Of Regents Of The University Of Texas System |
Treatment of fuchs' endothelial corneal dystrophy
|
|
NZ757927A
(en)
|
2017-04-11 |
2023-07-28 |
Arbutus Biopharma Corp |
Targeted compositions
|
|
WO2018215049A1
(en)
*
|
2017-05-23 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Process for galnac oligonucleotide conjugates
|
|
EP3633036A4
(en)
|
2017-05-26 |
2021-03-17 |
National Cerebral and Cardiovascular Center |
NUCLEIC ACID TARGETING ANTI-SENSES PCSK9
|
|
US20190055564A1
(en)
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
|
EP3630788A4
(en)
*
|
2017-06-02 |
2021-04-28 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THEIR USE
|
|
EP3599844A4
(en)
*
|
2017-06-07 |
2021-01-13 |
University of Massachusetts |
ANTI-ADAM33 OLIGONUCLEOTIDES AND RELATED PROCESSES
|
|
CN110799647A
(zh)
|
2017-06-23 |
2020-02-14 |
马萨诸塞大学 |
双尾自递送sirna及相关的方法
|
|
TW201919712A
(zh)
|
2017-08-10 |
2019-06-01 |
法商塞勒尼斯醫療控股公司 |
運送子(cargomers)
|
|
WO2019030313A2
(en)
|
2017-08-11 |
2019-02-14 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
|
|
CA3073213A1
(en)
|
2017-08-17 |
2019-02-21 |
Alnylam Pharmaceuticals, Inc. |
Tunable reversir tm compounds
|
|
WO2019036613A1
(en)
|
2017-08-18 |
2019-02-21 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF THE NOTCH SIGNALING PATHWAY FOR THE TREATMENT OF RESPIRATORY DISORDERS
|
|
WO2019038228A1
(en)
|
2017-08-22 |
2019-02-28 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
|
|
US10517889B2
(en)
|
2017-09-08 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of SMAD7 expression
|
|
SG11202001783YA
(en)
|
2017-10-12 |
2020-03-30 |
Wave Life Sciences Ltd |
Oligonucleotide compositions and methods thereof
|
|
JP2021502059A
(ja)
|
2017-10-13 |
2021-01-28 |
ロシュ イノベーション センター コペンハーゲン エーエス |
部分的に立体定義されたオリゴヌクレオチドのサブライブラリーを使用することによる、アンチセンスオリゴヌクレオチドの、改良された立体定義されたホスホロチオエートオリゴヌクレオチド変異体を同定するための方法
|
|
CR20210262A
(es)
|
2017-10-16 |
2022-06-27 |
Hoffmann La Roche |
MOLÉCULA DE ÁCIDOS NUCLEICOS PARA LA REDUCCIÓN DEL ARNm DE PAPD5 Y PAPD7 EN EL TRATAMIENTO DE LA INFECCIÓN DE LA HEPATITIS B (DIVISIONAL DEL EXPEDIENTE 2020-0205)
|
|
WO2019090359A1
(en)
|
2017-11-06 |
2019-05-09 |
Nitto Denko Corporation |
Fusogenic compounds for delivery of biologically active molecules
|
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
|
JP7727308B2
(ja)
|
2017-12-01 |
2025-08-21 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
二本鎖オリゴヌクレオチド、二本鎖オリゴヌクレオチドを含む組成物および複合体ならびに調製方法と使用
|
|
US12083142B2
(en)
|
2017-12-01 |
2024-09-10 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate comprising the same, and preparation method and use thereof
|
|
JP7365052B2
(ja)
|
2017-12-01 |
2023-10-19 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
JP7273417B2
(ja)
|
2017-12-01 |
2023-05-15 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
|
|
US11414661B2
(en)
|
2017-12-01 |
2022-08-16 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
|
|
IL319835A
(en)
|
2017-12-06 |
2025-05-01 |
Avidity Biosciences Inc |
Compositions and methods for treating muscular dystrophy and myotonic dystrophy
|
|
WO2019115416A2
(en)
|
2017-12-11 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating fndc3b expression
|
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
|
KR20200104339A
(ko)
|
2017-12-21 |
2020-09-03 |
에프. 호프만-라 로슈 아게 |
Htra1 rna 길항제에 대한 동반 진단제
|
|
WO2019126641A2
(en)
|
2017-12-21 |
2019-06-27 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
JP2021508327A
(ja)
|
2017-12-22 |
2021-03-04 |
ロシュ イノベーション センター コペンハーゲン エーエス |
新規のチオホスホラミダイト
|
|
WO2019122279A1
(en)
|
2017-12-22 |
2019-06-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
|
CN111448317B
(zh)
|
2017-12-22 |
2025-07-04 |
罗氏创新中心哥本哈根有限公司 |
包含二硫代磷酸酯核苷间键的缺口聚物寡核苷酸
|
|
DK3732185T3
(da)
*
|
2017-12-29 |
2025-03-31 |
Suzhou Ribo Life Science Co Ltd |
Konjugater og fremstilling og anvendelse heraf
|
|
WO2019137883A1
(en)
|
2018-01-10 |
2019-07-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating pias4 expression
|
|
SG11202006142PA
(en)
|
2018-01-12 |
2020-07-29 |
Roche Innovation Ct Copenhagen As |
Alpha-synuclein antisense oligonucleotides and uses thereof
|
|
CN111819283A
(zh)
|
2018-01-12 |
2020-10-23 |
百时美施贵宝公司 |
靶向α-突触核蛋白的反义寡核苷酸及其用途
|
|
CN111556894A
(zh)
|
2018-01-12 |
2020-08-18 |
哥本哈根罗氏创新中心 |
用于调控gsk3b表达的寡核苷酸
|
|
US11447775B2
(en)
|
2018-01-12 |
2022-09-20 |
Bristol-Myers Squibb Company |
Antisense oligonucleotides targeting alpha-synuclein and uses thereof
|
|
JP2021511072A
(ja)
|
2018-01-15 |
2021-05-06 |
アイオニス・ファーマシューティカルズ・インコーポレイテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． |
Ｄｎｍ２発現のモジュレーター
|
|
CN111615558A
(zh)
|
2018-01-17 |
2020-09-01 |
罗氏创新中心哥本哈根有限公司 |
用于调节erc1表达的寡核苷酸
|
|
US20210095277A1
(en)
|
2018-01-18 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting srebp1
|
|
BR112020010436A2
(pt)
*
|
2018-01-26 |
2020-11-24 |
F. Hoffmann-La Roche Ag |
oligonucleotídeo radiomarcado, processos para a preparação de um oligonucleotídeo radiomarcado, uso do oligonucleotídeo radiomarcado, método para determinar a biodistribuição e farmacocinética e oligonucleotídeo
|
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
|
WO2019154979A1
(en)
|
2018-02-09 |
2019-08-15 |
Genentech, Inc. |
Oligonucleotides for modulating tmem106b expression
|
|
MX2020008581A
(es)
|
2018-02-21 |
2020-09-21 |
Bristol Myers Squibb Co |
Oligonucleotidos antisentido de la proteina cinasa del tipo ii delta dependiente del calcio/calmodulina (camk2d) y sus usos.
|
|
EP3759127A4
(en)
|
2018-03-02 |
2022-03-30 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR MODULATING AMYLOID BETA PRECURSOR PROTEIN
|
|
TWI840345B
(zh)
|
2018-03-02 |
2024-05-01 |
美商Ionis製藥公司 |
Irf4表現之調節劑
|
|
CN111511915A
(zh)
|
2018-03-09 |
2020-08-07 |
第一三共株式会社 |
糖原病Ia型治疗药
|
|
US11661601B2
(en)
|
2018-03-22 |
2023-05-30 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating FMR1 expression
|
|
RU2020135289A
(ru)
|
2018-04-05 |
2022-05-05 |
Ф. Хоффманн-Ля Рош Аг |
Применение ингибиторов fubp1 для лечения инфекции вирусом гепатита в
|
|
AU2019252667A1
(en)
|
2018-04-11 |
2020-10-01 |
Ionis Pharmaceuticals, Inc. |
Modulators of EZH2 expression
|
|
JP2021522808A
(ja)
|
2018-05-07 |
2021-09-02 |
ロシュ イノベーション センター コペンハーゲン エーエス |
オリゴヌクレオチド治療剤の超並列発見方法
|
|
EP3790971A1
(en)
|
2018-05-08 |
2021-03-17 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
EP3790972A1
(en)
|
2018-05-08 |
2021-03-17 |
Regulus Therapeutics Inc. |
Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
|
|
TW202003541A
(zh)
|
2018-05-09 |
2020-01-16 |
美商Ionis製藥公司 |
用於減少ａｔｘｎ３表現之化合物及方法
|
|
CR20200605A
(es)
|
2018-05-09 |
2021-01-29 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para la reducción de la expresión de fxi
|
|
AU2019266550A1
(en)
*
|
2018-05-11 |
2020-11-26 |
Alpha Anomeric Sas |
Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides
|
|
TWI844541B
(zh)
|
2018-05-11 |
2024-06-11 |
新加坡商波濤生命科學有限公司 |
寡核苷酸組成物及其使用方法
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
WO2019233922A1
(en)
|
2018-06-05 |
2019-12-12 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating atxn2 expression
|
|
US11833168B2
(en)
|
2018-06-14 |
2023-12-05 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for increasing STMN2 expression
|
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
|
SG11202012759XA
(en)
|
2018-07-03 |
2021-01-28 |
Hoffmann La Roche |
Oligonucleotides for modulating tau expression
|
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
|
KR20210033004A
(ko)
|
2018-07-13 |
2021-03-25 |
에프. 호프만-라 로슈 아게 |
Rtel1의 발현을 조절하기 위한 올리고뉴클레오티드
|
|
EP3823725A4
(en)
|
2018-07-17 |
2023-05-10 |
Aronora, Inc. |
METHODS FOR SAFELY REDUCING THROMBOPOIETIN
|
|
CA3106986A1
(en)
|
2018-07-25 |
2020-01-30 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing atxn2 expression
|
|
KR20210041537A
(ko)
*
|
2018-07-31 |
2021-04-15 |
로슈 이노베이션 센터 코펜하겐 에이/에스 |
포스포로트리티오에이트 뉴클레오사이드간 연결을 포함하는 올리고뉴클레오타이드
|
|
EP4122943B1
(en)
|
2018-07-31 |
2024-05-29 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
BR112021002440A2
(pt)
|
2018-08-10 |
2021-05-04 |
University Of Massachusetts |
oligonucleotídeos modificados visando snps
|
|
US11918600B2
(en)
|
2018-08-21 |
2024-03-05 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
|
|
WO2020041769A1
(en)
|
2018-08-23 |
2020-02-27 |
University Of Massachusetts |
O-methyl rich fully stabilized oligonucleotides
|
|
CN112585280A
(zh)
|
2018-08-23 |
2021-03-30 |
罗氏创新中心哥本哈根有限公司 |
微小rna-134生物标志物
|
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
|
JP2021536239A
(ja)
|
2018-08-28 |
2021-12-27 |
ロシュ イノベーション センター コペンハーゲン エーエス |
スプライス調節化合物を使用したネオアンチゲン操作
|
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
|
WO2020051398A1
(en)
*
|
2018-09-06 |
2020-03-12 |
Aptamir Therapeutics, Inc. |
Metabolic benefits of short mir-22 mirna antagomir therapies
|
|
CN111655297A
(zh)
|
2018-09-30 |
2020-09-11 |
苏州瑞博生物技术有限公司 |
一种siRNA缀合物及其制备方法和用途
|
|
EP3873920A1
(en)
|
2018-11-01 |
2021-09-08 |
F. Hoffmann-La Roche AG |
Antisense oligonucleotides targeting tia1
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
AR117094A1
(es)
|
2018-11-15 |
2021-07-07 |
Ionis Pharmaceuticals Inc |
Moduladores de expresión irf5
|
|
JP7455831B2
(ja)
|
2018-11-21 |
2024-03-26 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
プリオン発現を低減するための化合物及び方法
|
|
EP3894559A4
(en)
|
2018-12-03 |
2023-04-05 |
Triplet Therapeutics, Inc. |
METHODS OF TREATMENT OF TRINUCLEOTIDE REPEAT EXPANSION DISORDERS RELATED TO MLH3 ACTIVITY
|
|
CN113631709A
(zh)
|
2018-12-20 |
2021-11-09 |
普拉克西斯精密药物股份有限公司 |
用于治疗kcnt1相关病症的组合物和方法
|
|
JP2022514648A
(ja)
|
2018-12-21 |
2022-02-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｃａｒｄ９を標的とするアンチセンスオリゴヌクレオチド
|
|
EP3903830A4
(en)
|
2018-12-28 |
2023-04-26 |
Suzhou Ribo Life Science Co., Ltd. |
NUCLEIC ACID, COMPOSITION AND CONJUGATE WITH NUCLEIC ACID, PROCESS FOR THEIR PREPARATION AND ITS USE
|
|
CN113614232A
(zh)
*
|
2019-01-18 |
2021-11-05 |
马萨诸塞大学 |
动态药代动力学修饰锚
|
|
EP3914232A1
(en)
*
|
2019-01-25 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Lipid vesicle for oral drug delivery
|
|
WO2020160453A1
(en)
|
2019-01-31 |
2020-08-06 |
Ionis Pharmaceuticals, Inc. |
Modulators of yap1 expression
|
|
WO2020169696A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Novel phosphoramidites
|
|
MX2021009950A
(es)
*
|
2019-02-20 |
2021-09-21 |
Roche Innovation Ct Copenhagen As |
Oligonucleotidos gapmeros de fosfonoacetato.
|
|
CN113474633A
(zh)
|
2019-02-26 |
2021-10-01 |
罗氏创新中心哥本哈根有限公司 |
寡核苷酸配制方法
|
|
JP7492526B2
(ja)
|
2019-02-27 |
2024-05-29 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
Ｍａｌａｔ１発現のモジュレーター
|
|
WO2020178258A1
(en)
*
|
2019-03-05 |
2020-09-10 |
F. Hoffmann-La Roche Ag |
Intracellular targeting of molecules
|
|
UA128437C2
(uk)
|
2019-03-29 |
2024-07-10 |
Айоніс Фармасьютикалз, Інк. |
Сполуки і способи модулювання ube3a-ats
|
|
EP3947678A1
(en)
|
2019-04-02 |
2022-02-09 |
ProQR Therapeutics II B.V. |
Antisense oligonucleotides for immunotherapy
|
|
AU2020252374A1
(en)
|
2019-04-03 |
2021-11-11 |
Bristol-Myers Squibb Company |
ANGPTL2 antisense oligonucleotides and uses thereof
|
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
|
JP7499267B2
(ja)
|
2019-04-04 |
2024-06-13 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ａｔｘｎ２発現を調節するためのオリゴヌクレオチド
|
|
AU2020280438B2
(en)
|
2019-05-22 |
2025-03-06 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
SG11202112741XA
(en)
|
2019-05-31 |
2021-12-30 |
Aligos Therapeutics Inc |
Modified gapmer oligonucleotides and methods of use
|
|
WO2020245233A1
(en)
|
2019-06-06 |
2020-12-10 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
|
WO2021021673A1
(en)
|
2019-07-26 |
2021-02-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
|
WO2021021959A2
(en)
*
|
2019-07-30 |
2021-02-04 |
Mpeg La, L.L.C. |
Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity
|
|
AU2020329155A1
(en)
|
2019-08-09 |
2022-03-10 |
University Of Massachusetts |
Chemically modified oligonucleotides targeting SNPs
|
|
WO2021049504A1
(ja)
|
2019-09-10 |
2021-03-18 |
第一三共株式会社 |
肝臓送達用ＧａｌＮＡｃ－オリゴヌクレオチドコンジュゲートおよび製造方法
|
|
US12365894B2
(en)
|
2019-09-16 |
2025-07-22 |
University Of Massachusetts |
Branched lipid conjugates of siRNA for specific tissue delivery
|
|
WO2021067825A1
(en)
*
|
2019-10-02 |
2021-04-08 |
Sirnaomics, Inc. |
Oligonucleotides with nucleoside analogs
|
|
EP4077670A1
(en)
|
2019-12-19 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Use of cops3 inhibitors for treating hepatitis b virus infection
|
|
US20230020092A1
(en)
*
|
2019-12-19 |
2023-01-19 |
Entrada Therapeutics, Inc. |
Compositions for delivery of antisense compounds
|
|
WO2021122910A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of sbds inhibitors for treating hepatitis b virus infection
|
|
EP4077667A1
(en)
|
2019-12-19 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Use of sept9 inhibitors for treating hepatitis b virus infection
|
|
CN114829599A
(zh)
|
2019-12-19 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途
|
|
WO2021122993A1
(en)
|
2019-12-19 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Use of saraf inhibitors for treating hepatitis b virus infection
|
|
AR120817A1
(es)
|
2019-12-20 |
2022-03-23 |
Hoffmann La Roche |
Oligonucleótidos mejorados para inhibir la expresión de scn9a
|
|
CA3163490A1
(en)
|
2019-12-24 |
2021-07-01 |
F. Hoffman-La Roche Ag |
Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
|
|
AU2020415322A1
(en)
|
2019-12-24 |
2022-06-16 |
F. Hoffmann-La Roche Ag |
Pharmaceutical combination of antiviral agents targeting HBV and/or an immune modulator for treatment of HBV
|
|
CA3161513A1
(en)
|
2020-01-28 |
2021-08-05 |
Irwin DAVIDSON |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
|
WO2021158810A1
(en)
|
2020-02-05 |
2021-08-12 |
Bristol-Myers Squibb Company |
Oligonucleotides for splice modulation of camk2d
|
|
WO2021170697A1
(en)
|
2020-02-28 |
2021-09-02 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating cd73 exon 7 splicing
|
|
AU2021225957A1
(en)
|
2020-02-28 |
2022-09-08 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating SMN2
|
|
KR20230011913A
(ko)
*
|
2020-03-04 |
2023-01-25 |
버브 테라퓨틱스, 인크. |
표적화된 rna 전달을 위한 조성물 및 방법
|
|
US11555190B2
(en)
|
2020-03-19 |
2023-01-17 |
Avidity Biosciences, Inc. |
Compositions and methods of treating Facioscapulohumeral muscular dystrophy
|
|
WO2021216785A1
(en)
*
|
2020-04-21 |
2021-10-28 |
Flagship Pioneering, Inc. |
Bifunctional molecules and methods of using thereof
|
|
WO2021222768A2
(en)
|
2020-05-01 |
2021-11-04 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating atxn1
|
|
CN115698290A
(zh)
|
2020-05-11 |
2023-02-03 |
基因泰克公司 |
用于治疗神经系统疾病的补体组分4抑制剂以及使用它们的相关组合物、系统和方法
|
|
WO2021231210A1
(en)
|
2020-05-11 |
2021-11-18 |
Genentech, Inc. |
Complement component c1r inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
|
|
EP4149486A1
(en)
|
2020-05-11 |
2023-03-22 |
Genentech, Inc. |
Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same
|
|
JP2023526267A
(ja)
|
2020-05-13 |
2023-06-21 |
エフ． ホフマン－ラ ロシュ アーゲー |
プログラニュリン標的オリゴヌクレオチドアゴニスト
|
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
EP4150086A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
|
EP4150076A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
EP4150078A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
|
EP4150088A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
JP2023526096A
(ja)
|
2020-05-22 |
2023-06-20 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｃａｒｄ９のスプライス調節のためのオリゴヌクレオチド
|
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
|
CN115702243A
(zh)
|
2020-06-09 |
2023-02-14 |
罗氏创新中心哥本哈根有限公司 |
用于治疗性多核苷酸的鸟苷类似物
|
|
AR122731A1
(es)
|
2020-06-26 |
2022-10-05 |
Hoffmann La Roche |
Oligonucleótidos mejorados para modular la expresión de fubp1
|
|
AU2021299290A1
(en)
|
2020-06-29 |
2023-01-05 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating PLP1
|
|
CN116209761A
(zh)
|
2020-07-23 |
2023-06-02 |
豪夫迈·罗氏有限公司 |
靶向rna结合蛋白位点的寡核苷酸
|
|
WO2022018155A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotides for splice modulation of stmn2
|
|
KR20230043914A
(ko)
|
2020-07-28 |
2023-03-31 |
아이오니스 파마수티컬즈, 인코포레이티드 |
App 발현을 감소시키기 위한 화합물 및 방법
|
|
CN111671913B
(zh)
*
|
2020-07-30 |
2022-02-08 |
四川大学 |
一种量子点-小核酸偶联物及其用途
|
|
WO2022032060A2
(en)
|
2020-08-07 |
2022-02-10 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating scn2a
|
|
CN116157522A
(zh)
|
2020-08-21 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
A1cf抑制剂用于治疗乙型肝炎病毒感染的用途
|
|
WO2022072950A1
(en)
*
|
2020-10-02 |
2022-04-07 |
Sirnaomics, Inc. |
NUCLEOSIDE CONTAINING siRNAS FOR TREAT VIRAL DISEASES
|
|
LT4136092T
(lt)
|
2020-11-18 |
2024-09-25 |
Ionis Pharmaceuticals, Inc. |
Junginiai ir būdai, skirti angiotenzinogeno raiškos moduliavimui
|
|
TW202237843A
(zh)
|
2020-12-03 |
2022-10-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向ａｔｘｎ３之反義寡核苷酸
|
|
TW202237842A
(zh)
|
2020-12-03 |
2022-10-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向ａｔｘｎ３之反義寡核苷酸
|
|
TW202229553A
(zh)
|
2020-12-18 |
2022-08-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向顆粒蛋白前體之反義寡核苷酸
|
|
AR124408A1
(es)
|
2020-12-18 |
2023-03-22 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para modular el factor xii
|
|
JP2024501662A
(ja)
|
2020-12-22 |
2024-01-15 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｘｂｐ１を標的とするオリゴヌクレオチド
|
|
CN114716518A
(zh)
*
|
2021-01-06 |
2022-07-08 |
圣诺制药公司 |
一种能够抑制pcsk9表达的分子构造及药物组合物
|
|
US20240083990A1
(en)
|
2021-01-26 |
2024-03-14 |
Universite Brest Bretagne Occidentale |
Novel stim1 splicing variants and uses thereof
|
|
TW202246500A
(zh)
|
2021-02-02 |
2022-12-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
|
|
MX2023010535A
(es)
|
2021-03-08 |
2023-09-19 |
Servier Lab |
Oligonucleotidos antisentido para inhibir la expresion de la alfa-sinucleina.
|
|
WO2022232650A1
(en)
*
|
2021-04-30 |
2022-11-03 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing agt expression
|
|
US20240263177A1
(en)
|
2021-05-20 |
2024-08-08 |
Korro Bio, Inc. |
Methods and Compositions for Adar-Mediated Editing
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
AU2022288115A1
(en)
|
2021-06-08 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Oligonucleotide progranulin agonists
|
|
US12378267B2
(en)
|
2021-06-17 |
2025-08-05 |
Entrada Therapeutics, Inc. |
Synthesis of FMOC-protected morpholino monomers and oligomers
|
|
JP2024523364A
(ja)
|
2021-06-18 |
2024-06-28 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
Ｉｆｎａｒ１発現を低減するための化合物及び方法
|
|
BR112023026862A2
(pt)
|
2021-06-23 |
2024-03-05 |
Beth Israel Deaconess Medical Ct Inc |
Compostos de oligonucleotídeos anti-flt1 otimizados para tratamento de pré-eclâmpsia e outros distúrbios angiogênicos
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
WO2023034561A2
(en)
*
|
2021-09-02 |
2023-03-09 |
Vanderbilt University |
Lipophilic oligonucleotide conjugates
|
|
KR20240055874A
(ko)
|
2021-09-16 |
2024-04-29 |
어비디티 바이오사이언시스 인크. |
안면견갑상완 근이영양증을 치료하는 조성물 및 방법
|
|
US20250352667A1
(en)
|
2021-10-22 |
2025-11-20 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
EP4426833A1
(en)
|
2021-11-03 |
2024-09-11 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating apolipoprotein e4 expression
|
|
CA3234478A1
(en)
|
2021-11-11 |
2023-05-19 |
Souphalone LUANGSAY |
Pharmaceutical combinations for treatment of hbv
|
|
WO2023102188A1
(en)
*
|
2021-12-03 |
2023-06-08 |
Quralis Corporation |
Gapmer antisense oligonucleotides with modified backbone chemistries
|
|
EP4444882A1
(en)
|
2021-12-07 |
2024-10-16 |
F. Hoffmann-La Roche AG |
Antisense oligonucleotides targeting actl6b
|
|
EP4448763A1
(en)
|
2021-12-17 |
2024-10-23 |
F. Hoffmann-La Roche AG |
Oligonucleotide gba agonists
|
|
EP4448106A1
(en)
|
2021-12-17 |
2024-10-23 |
Hoffmann-La Roche Inc. |
Combination of oligonucleotides for modulating rtel1 and fubp1
|
|
WO2023117738A1
(en)
|
2021-12-20 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
|
WO2023141507A1
(en)
|
2022-01-20 |
2023-07-27 |
Genentech, Inc. |
Antisense oligonucleotides for modulating tmem106b expression
|
|
AR128558A1
(es)
|
2022-02-21 |
2024-05-22 |
Hoffmann La Roche |
Oligonucleótido antisentido
|
|
TW202345867A
(zh)
|
2022-03-16 |
2023-12-01 |
日商第一三共股份有限公司 |
抑制運鐵蛋白受體2表現的siRNA
|
|
CN118871585A
(zh)
|
2022-03-16 |
2024-10-29 |
第一三共株式会社 |
具有RNAi活性的化学-修饰的寡核苷酸
|
|
JP2025516554A
(ja)
|
2022-05-10 |
2025-05-30 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｃｆｐ－ｅｌｋ１遺伝子間領域を標的とするアンチセンスオリゴヌクレオチド
|
|
CN119213124A
(zh)
|
2022-05-18 |
2024-12-27 |
豪夫迈·罗氏有限公司 |
靶向rna结合蛋白位点的改进的寡核苷酸
|
|
EP4282964A1
(en)
*
|
2022-05-23 |
2023-11-29 |
Universitat de Valéncia |
Oligonucleotides conjugated to oleic acid and uses thereof
|
|
WO2023242324A1
(en)
|
2022-06-17 |
2023-12-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for targeting progranulin
|
|
EP4332221A1
(en)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
|
WO2024052403A1
(en)
|
2022-09-06 |
2024-03-14 |
F. Hoffmann-La Roche Ag |
Double-stranded rna molecule for administration to the eye
|
|
KR20250075637A
(ko)
|
2022-09-23 |
2025-05-28 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Mecp2 발현을 감소시키기 위한 화합물 및 방법(compounds and methods for reducing mecp2 expression)
|
|
KR20250116673A
(ko)
*
|
2022-11-21 |
2025-08-01 |
펩젠 인크. |
세포-침투 펩티드, 그의 접합체 및 그의 사용 방법
|
|
WO2024126654A1
(en)
|
2022-12-14 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
|
WO2024153586A1
(en)
|
2023-01-16 |
2024-07-25 |
Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement |
Antisense molecules and their uses for the treatment of coronavirus infection, in particular the treatment of covid-19 related to sars-cov-2 infection
|
|
KR20250162631A
(ko)
|
2023-01-19 |
2025-11-18 |
알토스 랩스, 인크. |
장기 이식에서의 재생 인자의 용도
|
|
WO2024196893A1
(en)
*
|
2023-03-17 |
2024-09-26 |
Camford Labs Inc. |
Chemically modified nucleotides
|
|
WO2024199445A1
(en)
*
|
2023-03-30 |
2024-10-03 |
Ractigen Therapeutics |
Vehicles for delivering oligonucleotides and methods of use thereof
|
|
WO2024227765A2
(en)
|
2023-05-04 |
2024-11-07 |
F. Hoffmann-La Roche Ag |
Oligonucleotides capable of upregulating glucocerebrosidase expression
|
|
TW202508607A
(zh)
*
|
2023-05-19 |
2025-03-01 |
大陸商北京炫景瑞醫藥科技有限公司 |
雙股寡核苷酸及其共軛物和用途
|
|
AR132975A1
(es)
|
2023-06-16 |
2025-08-13 |
Hoffmann La Roche |
Oligonucleótidos bicatenarios para modular la expresión de jak1
|
|
WO2025036916A1
(en)
|
2023-08-16 |
2025-02-20 |
Les Laboratoires Servier |
Oligonucleotides for modulating kcnt1 expression
|